Morphine sulfate tablets

Compare Morphine sulfate tablets  to:
Compare
Compare

Generic Name for Morphine sulfate tablets

Morphine sulfate 15mg, 30mg; scored tabs.

Legal Classification:

CII

Pharmacological Class for Morphine sulfate tablets

Opioid.

Manufacturer of Morphine sulfate tablets

Roxane Laboratories, Inc.

Indications for Morphine sulfate tablets

Moderate to severe pain.

Adult dose for Morphine sulfate tablets

Individualize and periodically reevaluate dose. Tabs: usually 15–30mg every 4hrs as needed. Soln: usually 10–20mg every 4hrs as needed. Terminal illness: may give on fixed dosing schedule.

Children's dosing for Morphine sulfate tablets

<18yrs: not recommended.

Also:

Contraindications for Morphine sulfate tablets

Respiratory depression. Acute or severe asthma or hypercarbia. Paralytic ileus.

Precautions for Morphine sulfate tablets

Head injury. Increased intracranial pressure. Shock. Severe renal or hepatic impairment. Impaired pulmonary, thyroid, or adrenocortical function. GI or GU obstruction. Acute abdomen. Biliary tract disease. Acute pancreatitis. Kyphoscoliosis. Convulsive disorders. Drug abusers. Delirium tremens. Elderly. Debilitated. Pregnancy (Cat.C). Labor & delivery, nursing mothers: not recommended.

Interactions for Morphine sulfate tablets

Potentiation with alcohol, CNS depressants, anticholinergics, MAOIs, phenothiazines, general anesthetics, antiemetics, p-glycoprotein inhibitors (eg, quinidine). Do not use within 14 days of MAOIs. Severe hypotension with phenothiazines, general anesthetics. Potentiates neuromuscular blockers. Monitor cimetidine. Possible withdrawal symptoms with mixed opioid agonist/antagonists.

Adverse Reactions for Morphine sulfate tablets

Somnolence, constipation, GI upset, lightheadedness, dizziness, sweating, respiratory depression, orthostatic hypotension, syncope, dysphoria, euphoria.

How is Morphine sulfate tablets supplied?

Tabs—100
Soln—100mL, 500mL

Related Disease:

Pain, general~narcotics

Related Resources

Exalgo approved for moderate to severe pain

March 02, 2010

The FDA has approved Exalgo (hydromorphone HCl extended-release tablets, from Covidien) for the management of moderate to severe pain in opioid-tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.

Phase 3 study of MoxDuo IR for pain management

February 10, 2010

QRxPharma Limited announced initiation of a second Phase 3 registration trial (Study 009) to evaluate its MoxDuo IR (morphine and oxycodone) product for the management of moderate to severe pain in patients who have undergone total knee replacement surgery.

FDA-approved morphine sulfate oral solution 100mg/5mL available

January 27, 2010

Roxane Laboratories announced that the New Drug Application (NDA) for high concentrate morphine sulfate oral solution 100mg/5mL (20mg/mL) has been approved by the FDA.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

NDA submitted for extended-release tapentadol tablets for chronic pain

December 02, 2009

Johnson & Johnson and its subsidiaries, PriCara and Ortho-McNeil-Janssen, announced that they have submitted a New Drug Application (NDA) to the FDA for tapentadol extended release (ER) tablets for the management of moderate to severe chronic pain in patients ≥18 years of age.